Intravitreal Bevacizumab for Treatment of Refractory Central Serous Choroidoretinopathy.
10.3341/kjo.2012.26.2.139
- Author:
Morteza ENTEZARI
1
;
Alireza RAMEZANI
;
Mehdi YASERI
Author Information
1. Ophthalmic Research Center, Department of Ophthalmology, Imam Hossein Medical Center, Shahid Beheshti University (MC), Tehran, Iran. entmort@hotmail.com
- Publication Type:Case Reports
- Keywords:
Bevacizumab;
Central serous choroidoretinopathy;
Optical coherence tomography
- MeSH:
Adult;
Angiogenesis Inhibitors/*administration & dosage;
Antibodies, Monoclonal, Humanized/*administration & dosage;
Central Serous Chorioretinopathy/*drug therapy/*pathology;
Female;
Follow-Up Studies;
Humans;
Intravitreal Injections;
Male;
Middle Aged;
Tomography, Optical Coherence;
Treatment Outcome;
Visual Acuity/drug effects
- From:Korean Journal of Ophthalmology
2012;26(2):139-142
- CountryRepublic of Korea
- Language:English
-
Abstract:
In a clinical case series, 5 patients with not-resolved central serous choroidoretinopathy (CSC) lasting more than 1 year received one intravitreal bevacizumab injection (IVB, 1.25 mg) injection. All patients underwent a through ophthalmic examination 1 day, 1 week, and 1, 2, and 6 months after the injection. Best corrected visual acuity (BCVA) and central macular thickness were compared before and after treatment by optical coherence tomography. Mean BCVA was improved significantly (p = 0.020) from 0.60 +/- 0.25 to 0.50 +/- 0.18 and 0.29 +/- 0.19 logarithm of minimum angle of resolution at 6 and 18 weeks, respectively. Central macular thickness was also decreased significantly (p = 0.010) from 370 +/- 65 to 208 +/- 23 microm at 4 months. No recurrence was occurred during follow-up. IVB injection may have beneficial effect in the treatment of refractory CSC.
